In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. acquired resistance to itraconazole

Scandinavian Journal of Infectious Diseases

Volumn 29, Issue 5, 1997, Pages 509-512

  Chryssanthou, Erja ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ITRACONAZOLE;

ARTICLE; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DILUTION; DRUG SENSITIVITY; LONG TERM CARE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN DIFFERENCE;

EID: 0030659412     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365549709011864     Document Type: Article

References (24)

1. Bodey GP. Aspergillosis. Eur J Clin Microbiol 1989; 8: 413 37.
2. Horvath JA, Dummer S. The use of respiratory tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100: 171 8.
3. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-15.
4. Souha KS, Welly-Wolf K, Madden J, Tapson V, Baz MA, Davis RD, Perfect JR. Fungal infections in lung and heart lung transplant recipients: report of 9 cases and review of the literature. Med 1996; 75: 142-56.
5. Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989; 86: 791 800.
6. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewanup DH, et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135-44.
7. Espinel-Ingroff A, Dawson K, Pfaller M, Anaissie E, Breslin B, Dixon D, et al. Comparative and collaborative evaluation of standardisation of antifungal susceptibility testing of filamentous fungi. Antimicrob Agents Chemother 1995; 39: 314 9.
8. Gehrt A, Peter J, Pizzo PA, Walsh TJ. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J Clin Microbiol 1995; 33: 1302-7.
9. Manavathu EK, Alangaden GJ, Lerner SA. A comparative study of the broth micro- and macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus. Can J Microbiol 1996; 42: 960-4.
10. Pujol I, Guarro J, Llop C, Soler L, Fernandez-Ballart J. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi. Antimicrob Agent Chemother 1996; 40: 2106-10.
11. Dermoumi H. In vitro susceptibility of fungal isolates of clinically important specimens to itraconazole, fluconazole and amphotericin B. Chemotherapy 1994; 40: 92-8.
12. Dc Hoog GS, Guarro J. Atlas of Clinical Fungi. Baarn and Delft. Centraalbureau voor Schimmelcultures, 1995.
13. Denning DW, Hanson LH, Stevens DA. In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole against Aspergillus species. Eur J Clin Microbiol Infect Dis 1990; 9: 693-7.
14. Espinel-Ingroff A, Kerkering TM. Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi. J Clin Microbiol 1991; 29: 393 4.
15. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast. Proposed standard M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pensylvania, 1992.
16. Pfaller MA, Bale M, Buschelman B, Lancaster M, Espinel-Ingroff A, Rex JH, Rinaldi MG, Cooper CR, McGinnis MR. Quality control guidelines for National Committee for Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol 1995; 33: 1104-7.
17. Rex JH, Pfaller MA, Lancaster M, Odds FC, Bolmström A, Rinaldi MG. Quality control guidelines for National Committee for Laboratory Standards-recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol 1996; 34: 816-7.
18. Colombo AL, McGough DA, Rinaldi MG. Discrepancies between MIC and MLC values pf amphotericin B against isolates of Aspergillus species. Mycopathologia 1994; 128: 129-33.
19. Denning DW, Hanson LH, Perlman AM, Stevens DA. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 1992: 15: 21-34.
20. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990; 23: 607-14.
21. Caras WE, Pluss JL. Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Mayo Clin Proc 1996; 71: 25-30.
22. Sekhon AS, Padhye AA, Garg AK, Hamir Z. Effects of culture media on the in vitro susceptibility of selected opportunistic fungi to fluconazole and itraconazole. Chemotherapy 1992; 38: 169-73.
23. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990; 12: 1147-201.
24. Hosteller JS, Heykants J, Clemons KV, Woestenborghs R, Hanson LH, Stevens DA. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agent Chemother 1993; 37: 2224-7.